Hubungan Penggunaan Obat Antipsikotik dengan Kepatuhan Minum Obat pada Pasien Skizofrenia : A Cross-Sectional Study

Nurul Amna; Ellyza Fazlylawati; Khaira Rizki; Urip Pratama

doi:10.55606/termometer.v3i3.5446

Authors

Nurul Amna Universitas Abulyatama
Ellyza Fazlylawati Universitas Abulyatama
Khaira Rizki Universitas Abulyatama
Urip Pratama Universitas Abulyatama

DOI:

https://doi.org/10.55606/termometer.v3i3.5446

Keywords:

Antipsychotics, Health, Medication adherenc, Quality of life, Schizophrenia

Abstract

Medication non-compliance in schizophrenia patients has the potential to have significant negative impacts on the patient's clinical condition, the continuation of therapy, and the surrounding social environment. Low medication adherence can lead to symptom relapse, increased hospitalization rates, and a decreased quality of life. Therefore, efforts to minimize these impacts need to be directed at improving medication adherence, one of which is through identifying factors that influence adherence and selecting appropriate antipsychotic medications. This study aims to determine the relationship between antipsychotic medication use and medication adherence in schizophrenia patients. The research design used was a quantitative cross-sectional study approach. The study sample size was 195 respondents, obtained using a systematic random sampling method. The research instruments included an antipsychotic medication use sheet and the Morisky Medication Adherence Scale (MMAS). Data analysis was performed using the Chi-Square test to determine the significance of the relationship. The results showed that patients given typical antipsychotic medications had a higher adherence percentage (49.4%) compared to patients receiving atypical antipsychotic medications (27%) or a combination (23.6%). These findings confirm a significant relationship between the type of antipsychotic medication and patient adherence (χ² = 7.307; p = 0.026). The study's conclusions emphasize that the choice of antipsychotic, particularly typical antipsychotics, can be an important factor in improving medication adherence in patients with schizophrenia. Therefore, healthcare professionals are expected to carefully consider the type of medication prescribed, while still taking into account the patient's clinical condition, side effects, and individual needs, so that adherence and therapeutic success can be optimized.

Downloads

Download data is not yet available.

References

Ata, E. E., Bahadir-Yilmaz, E., & Bayrak, N. G. (2020). The impact of side effects on schizophrenia and bipolar disorder patients' adherence to prescribed medical therapy. Perspectives in Psychiatric Care, 56(3), 691–696. https://doi.org/10.1111/ppc.12483

Bardin, A., Cheney, B., & Braider, L. (2019). Increasing psychiatric treatment engagement and adherence in the college population. In V. Fornari & I. Dancyger (Eds.), Springer Nature Switzerland AG (pp. 57–70). https://doi.org/10.1007/978-3-030-12665-0_5

Caqueo-Urízar, A., Urzúa, A., Mena-Chamorro, P., Fond, G., & Boyer, L. (2020). Adherence to antipsychotic medication and quality of life in Latin-American patients diagnosed with schizophrenia. Patient Preference and Adherence, 14, 1595–1604. https://doi.org/10.2147/PPA.S265312

Chaudhari, B., Saldanha, D., Kadiani, A., & Shahani, R. (2017). Evaluation of treatment adherence in outpatients with schizophrenia. Industrial Psychiatry Journal, 26(2), 215–220. https://doi.org/10.4103/ipj.ipj_24_17

Eticha, T., Teklu, A., Ali, D., Solomon, G., & Alemayehu, A. (2015). Factors associated with medication adherence among patients with schizophrenia in Mekelle, Northern Ethiopia. PLoS ONE, 10(3), e0120560. https://doi.org/10.1371/journal.pone.0120560

Fenton, W. S., Blyler, C. R., & Heinssen, R. K. (1997). Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bulletin, 23(4), 637–651. https://doi.org/10.1093/schbul/23.4.637

Gast, A., & Tim, M. (2019). Medication adherence influencing factors—An updated overview of systematic reviews. Systematic Reviews, 8(112), 1–18. https://doi.org/10.1186/s13643-019-1014-8

Ih, H., Putri, R. A., & Untari, E. K. (2016). Different type of antipsychotic therapies on length of stay of acute schizophrenia patients in Sungai Bangkong Regional Mental Hospital Pontianak. Indonesian Journal of Clinical Pharmacy, 5(2), 115–122. https://doi.org/10.15416/ijcp.2016.5.2.115

Jovanka, I., Wahyuni, S., & Woferst, R. (2023). Strategi keluarga dalam pemberian obat antipsikotik pada anggota keluarga dengan gangguan jiwa. Jurnal Ilmu Kedokteran dan Kesehatan Indonesia, 3(1), 80–90. https://doi.org/10.55606/jikki.v3i1.1111

Khayyat, S. M., Khayyat, S. M. S., Hyat Alhazmi, R. S., Mohamed, M. M. A., & Hadi, M. A. (2017). Predictors of medication adherence and blood pressure control among Saudi hypertensive patients attending primary care clinics: A cross-sectional study. PLoS ONE, 12(1), e0171255. https://doi.org/10.1371/journal.pone.0171255

Marrero, R. J., Fumero, A., de Miguel, A., & Peñate, W. (2020). Psychological factors involved in psychopharmacological medication adherence in mental health patients: A systematic review. Patient Education and Counseling, 103(10), 2116–2131. https://doi.org/10.1016/j.pec.2020.04.030

Muench, J., & Hamer, A. M. (2010). Adverse effects of antipsychotic medications. American Family Physician, 81(5), 617–622.

Mullins, C. D., Shaya, F. T., & Weir, M. R. (2008). Adherence and persistence in the treatment of schizophrenia: Issues and recommendations. Journal of Pharmacy Practice, 21(1), 3–12. https://doi.org/10.1177/0897190007311471

Phan, S. V. (2016). Medication adherence in patients with schizophrenia. International Journal of Psychiatry in Medicine, 51(2), 211–219. https://doi.org/10.1177/0091217416636601

Purba, J. M., Simamora, R. H., & Karota, E. (2021). The relationship of medication adherence and social functioning of persons with schizophrenia in the long-term period. Open Access Macedonian Journal of Medical Sciences, 9(1), 16–18. https://doi.org/10.3889/oamjms.2021.6302

Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Capuano, G. A., & Hsiao, J. K. (2007). Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. American Journal of Psychiatry, 164(3), 415–427. https://doi.org/10.1176/ajp.2007.164.3.415

Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Rosenheck, R. A., & Hsiao, J. K. (2006). Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry, 163(4), 611–622. https://doi.org/10.1176/ajp.2006.163.4.611

Tan, X., Patel, I., & Chang, J. (2014). Review of the four-item Morisky Medication Adherence Scale (MMAS-4) and eight-item Morisky Medication Adherence Scale (MMAS-8). Innovations in Pharmacy, 5(3), 1–7. https://doi.org/10.24926/iip.v5i3.347

Tham, X. C., Xie, H., Chng, C. M. L., Seah, X. Y., Lopez, V., & Klainin-Yobas, P. (2018). Exploring predictors of medication adherence among inpatients with schizophrenia in Singapore’s mental health settings: A non-experimental study. Archives of Psychiatric Nursing, 32(4), 536–548. https://doi.org/10.1016/j.apnu.2018.02.004

World Health Organization. (2019). Mental disorders. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/mental-disorders

Zygmunt, A., Olfson, M., Boyer, C. A., & Mechanic, D. (2002). Interventions to improve medication adherence in schizophrenia. American Journal of Psychiatry, 159(10), 1653–1664. https://doi.org/10.1176/appi.ajp.159.10.1653